Pancreatic Cancer

Why trials studying Pancreatic Cancer stopped, in this sample of ClinicalTrials.gov.

51 stopped trials with a clear reason; 92% ended for non-scientific reasons.

Trials

• Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study
  NCT07173374 · SUSPENDED · slow accrual
  “The study was terminated early due to slow patient accrual. Enrollment was substantially lower than anticipated, making it unlikely to achieve the planned sample size within a reasonable timeframe.”
• A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
  NCT06091930 · TERMINATED · funding business
  “Sponsor decision”
• Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
  NCT05631574 · TERMINATED · funding business
  “Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.”
• FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
  NCT05395052 · TERMINATED · funding business
  “This study was terminated by the Sponsor.”
• Role of Proton Pump Inhibitors on the Postoperative Course Following Pancreaticoduodenectomy
  NCT05251233 · TERMINATED · logistics pi
  “Investigator and study team chose to end study early.”
• Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
  NCT05194735 · TERMINATED · funding business
  “Funding”
• Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
  NCT04683939 · TERMINATED · funding business
  “Sponsor decision”
• MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC
  NCT05114213 · TERMINATED · slow accrual
  “Low accrual, close out in November 2025”
• OH2 Oncolytic Viral Therapy in Pancreatic Cancer
  NCT04637698 · TERMINATED · funding business
  “Strategy adjustment”
• A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
  NCT04682431 · TERMINATED · funding business
  “Sponsor business decision.”
• Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
  NCT04034745 · WITHDRAWN · funding business
  “lack of funding”
• A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）
  NCT04420130 · WITHDRAWN · regulatory
  “Failed to pass ethics committee review”
• A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
  NCT04193904 · TERMINATED · funding business
  “Sponsor insolvency”
• Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry
  NCT03724435 · TERMINATED · other
  “Competing trial will publish similar results”
• A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
  NCT03960060 · TERMINATED · funding business
  “Adjustment of study strategy”
• Biological Effect of Warfarin on Pancreatic Cancer
  NCT03536208 · WITHDRAWN · slow accrual
  “no accrual for over 12 months”
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
  NCT03829501 · TERMINATED · funding business
  “Early discontinuation based on strategic sponsor decision not driven by any safety concerns.”
• Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
  NCT03520790 · TERMINATED · futility
  “Phase II was not pursued due to futility based on the results of the NAPOLI-3 therapeutic clinical trial.”
• Kinetics of Microparticles Under Chemotherapy in Patients With Gastric or Pancreatic Cancer
  NCT03471468 · TERMINATED · slow accrual
  “Low recruitment”
• Modified Wet Suction Versus Capillary Techniques for EUS Guided Fine Needle Aspiration and Biopsy of Solid Lesions
  NCT02919553 · WITHDRAWN · funding business
  “decided not to proceed with study at this time”
• CAR T Cell Immunotherapy for Pancreatic Cancer
  NCT03323944 · TERMINATED · logistics pi
  “Administrative reasons”
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
  NCT03207867 · TERMINATED · funding business
  “Sponsor decision”
• A Study of the Efficacy of ONS to Reduce Postoperative Complications Associated With Pancreatic Surgery
  NCT03244683 · TERMINATED · slow accrual
  “Closed due to low enrollment”
• Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
  NCT03848182 · TERMINATED · slow accrual
  “Slow accrual”
• Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
  NCT02950025 · TERMINATED · slow accrual
  “Low accrual”
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
  NCT02576665 · TERMINATED · funding business
  “Sponsor decision”
• Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT02352831 · TERMINATED · funding business
  “Insufficient funding and drug supply from manufacturer”
• Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
  NCT02423954 · TERMINATED · logistics pi
  “Investigator no longer at site to enroll patients or write up data”
• Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures
  NCT02366858 · WITHDRAWN · logistics pi
  “PI decision was made to discontinue the study”
• An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
  NCT01929941 · TERMINATED · funding business
  “Business decision.”
• Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
  NCT01836432 · TERMINATED · funding business
  “Company decision”
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
  NCT01583686 · TERMINATED · slow accrual
  “Study terminated due to slow/insufficient accrual.”
• A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer
  NCT01940237 · TERMINATED · slow accrual
  “Low recruitment”
• Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
  NCT01531712 · TERMINATED · slow accrual
  “Due to a low recruitment rate since start of recruitment period.”
• A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
  NCT01240304 · TERMINATED · slow accrual
  “no subjects enrolled”
• Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
  NCT01188109 · TERMINATED · slow accrual
  “Slow accrual”
• Use of PET Imaging to Distinguish Malignant From Benign IPMN
  NCT01104116 · TERMINATED · logistics pi
  “Poor enrollment; PI left the institution”
• Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer
  NCT00878657 · TERMINATED · slow accrual
  “Slow accrual”
• Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine
  NCT00867126 · TERMINATED · slow accrual
  “low accrual”
• A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)
  NCT01050426 · TERMINATED · futility
  “Data from other trials failed to demonstrate meaningful survival advantage”
• Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
  NCT00766636 · TERMINATED · slow accrual
  “Slow Accrual”
• Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
  NCT00625586 · TERMINATED · funding business
  “Corporate decision”
• Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
  NCT00614601 · TERMINATED · funding business
  “Sponsor proceeded with a phase III study for same indication.”
• An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs
  NCT00414570 · TERMINATED · funding business
  “Retirement of former Qualified Investigator and lack of resources to complete study”
• Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
  NCT00662688 · TERMINATED · slow accrual
  “recruitment prematurely stopped due to a lack of eligible patients.”
• Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
  NCT00529113 · TERMINATED · funding business
  “To pursue other indications”
• Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery
  NCT01094535 · WITHDRAWN · slow accrual
  “Poor enrollment”
• Study of Respiratory Gated Proton Beam Radiotherapy for Inoperable Pancreas Carcinoma
  NCT00658801 · TERMINATED · slow accrual
  “difficult to register”
• Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
  NCT00281996 · TERMINATED · slow accrual
  “Closed to accrual to allow enrollment on another more promising trial.”
• Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
  NCT00066677 · TERMINATED · futility
  “Stopped accordining to early stopping rule for futility”
• Laparoscopic Ultrasound in Diagnosing Patients With Pancreatic Cancer
  NCT00003085 · TERMINATED · slow accrual
  “Insufficient Accrual”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.